Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

NCT02595905 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

344

Enrollment

NIH

Sponsor class

Conditions

Metastatic BRCA Hereditary Breast Carcinoma
Metastatic Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Metastatic Triple-Negative Breast Carcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Cisplatin
OTHER: Laboratory Biomarker Analysis
OTHER: Placebo Administration
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)